Pharma BD Deal Intelligence
Boehringer Ingelheim International GmbH / AimedBio Inc.
2025 · Licensing/Option · $991M · Complete
Boehringer Ingelheim licensed a preclinical antibody-drug conjugate from South Korea's AimedBio for development across a broad range of cancers. The ADC pairs a cancer-targeting monoclonal antibody with an exatecan-derivative cytotoxic payload and is expected to enter first-in-human trials in 2026. AimedBio is eligible for up to $991 million in total consideration - upfront plus development, regulatory and commercial milestones - and separate royalties on net sales. The upfront amount was not disclosed.
This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2030 at the earliest for this deal, once/if it closes.
Key facts
- Announced Oct 15, 2025
- Deal value $991M
- Deal type Licensing/Option
- Therapeutic area Oncology
- Indications Multiple solid tumors
- Key assets Undisclosed exatecan-payload antibody-drug conjugate
- Mechanism Antibody-drug conjugate with exatecan-derivative topoisomerase I inhibitor payload
Related deals
See the full interactive analysis, sources & comparables →
← Browse all deals ·
How we score deals
More: 2025 deals · Boehringer Ingelheim International GmbH deals · Oncology deals